Published in Proc Natl Acad Sci U S A on December 01, 1990
A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A (1991) 6.42
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer (2011) 1.97
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A (1993) 1.84
Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A (1992) 1.56
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1992) 1.33
Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut (1992) 1.31
Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol (1995) 1.17
Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer (1993) 1.15
Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci U S A (1993) 1.13
Overexpression of P53 and its risk factors in esophageal cancer in urban areas of Xi'an. World J Gastroenterol (1998) 1.08
Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today (1999) 1.05
Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer (2013) 1.05
Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis. Br J Cancer (1994) 1.04
Plasma microRNA profiles: identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer (2014) 1.04
Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer (1999) 0.97
Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut (2003) 0.96
Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg (2009) 0.95
Role of p53 in Cell Death and Human Cancers. Cancers (Basel) (2011) 0.95
p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol (1998) 0.94
Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg (1997) 0.93
p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol (1993) 0.93
Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci U S A (1994) 0.92
MicroRNA and its roles in esophageal cancer. Med Sci Monit (2012) 0.92
A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. Br J Cancer (1996) 0.91
Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut (1995) 0.90
Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res (2011) 0.90
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist (2013) 0.90
Esophageal Cancer: Insights From Mouse Models. Cancer Growth Metastasis (2015) 0.88
p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. J Clin Pathol (1995) 0.86
Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol (2010) 0.86
p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation. Cell Cycle (2012) 0.86
CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. Int J Clin Exp Pathol (2010) 0.86
P53 mutations in gastric carcinomas. Br J Cancer (1992) 0.85
The roles of post-translational modifications in the context of protein interaction networks. PLoS Comput Biol (2015) 0.85
In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. Am J Pathol (1992) 0.84
The tumor microenvironment in esophageal cancer. Oncogene (2016) 0.83
Molecular biology of Barrett's esophagus and esophageal cancer:role of p53. World J Gastroenterol (1998) 0.83
Genomic Characterization of Esophageal Squamous Cell Carcinoma Reveals Critical Genes Underlying Tumorigenesis and Poor Prognosis. Am J Hum Genet (2016) 0.83
Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. Br J Cancer (2010) 0.82
Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. J Biol Chem (2014) 0.82
None-endoscopic Screening for Esophageal Squamous Cell Carcinoma- A Review. Middle East J Dig Dis (2012) 0.82
Rat p53 gene mutations in primary Zymbal gland tumors induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. Proc Natl Acad Sci U S A (1992) 0.81
Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J Clin Pathol (2002) 0.81
Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. Br J Cancer (1995) 0.80
From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract (2015) 0.80
Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Cancer Sci (2015) 0.79
Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in oesophageal squamous cell carcinomas. Virchows Arch (1997) 0.78
Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma. Dig Dis Sci (2014) 0.78
p53 gene therapy for esophageal cancer. J Gastroenterol (2002) 0.77
DNA repair gene status in oesophageal cancer. Mol Pathol (1999) 0.77
Identification of New Candidate Genes and Chemicals Related to Esophageal Cancer Using a Hybrid Interaction Network of Chemicals and Proteins. PLoS One (2015) 0.76
Immortalisation of human oesophageal epithelial cells by a recombinant SV40 adenovirus vector. Br J Cancer (1995) 0.76
Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus. Br J Cancer (2007) 0.76
Demystified ... p53. Mol Pathol (1998) 0.75
Oncogens in ENT and head and neck - a review. Indian J Otolaryngol Head Neck Surg (1998) 0.75
Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers. Environ Health Perspect (1992) 0.75
Barrett's esophagus: model of neoplastic progression. World J Surg (2003) 0.75
Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma. Surg Today (1997) 0.75
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg (2017) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol (1987) 58.68
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
ras genes. Annu Rev Biochem (1987) 22.59
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Molecular basis of base substitution hotspots in Escherichia coli. Nature (1978) 13.79
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science (1983) 9.38
Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci U S A (1975) 8.66
The molecular genetics of cancer. Science (1987) 7.64
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
DNA repair enzymes. Annu Rev Biochem (1982) 6.68
INDUCTION OF SPECIFIC MUTATIONS WITH 5-BROMOURACIL. Proc Natl Acad Sci U S A (1958) 6.25
Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (1985) 5.69
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
The ras gene family and human carcinogenesis. Mutat Res (1988) 3.20
Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene (1989) 2.67
p53: oncogene or anti-oncogene? Genes Dev (1990) 2.60
Mutational specificity in bacteria. Annu Rev Genet (1983) 2.47
Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis (1988) 2.37
Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene (1987) 2.26
Mechanisms of chemical carcinogenesis: nature of proximate carcinogens and interactions with macromolecules. Pharmacol Rev (1966) 1.98
High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res (1986) 1.98
The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res (1988) 1.96
Carcinogen-mediated amplification of viral DNA sequences in simian virus 40-transformed Chinese hamster embryo cells. Proc Natl Acad Sci U S A (1981) 1.72
Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol (1990) 1.37
Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus. Cancer Res (1988) 1.33
Mutational specificity of alkylating agents and the influence of DNA repair. Environ Mol Mutagen (1990) 1.28
Hyperproduction and gene amplification of the epidermal growth factor receptor in squamous cell carcinomas. Jpn J Cancer Res (1985) 1.27
High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int J Cancer (1987) 1.26
Molecular analysis of O6-substituted guanine-induced mutagenesis of ras oncogenes. Proc Natl Acad Sci U S A (1989) 1.24
Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer (1988) 1.23
Sequence specificity of mutations induced by benzo[a]pyrene-7,8-diol-9,10-epoxide at endogenous aprt gene in CHO cells. Somat Cell Mol Genet (1988) 1.21
O(6)-methyldeoxyguanosine in oesophageal DNA among individuals at high risk of oesophageal cancer. Int J Cancer (1985) 1.17
Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res (1988) 1.14
High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res (1989) 1.13
Mutational activation of the cellular Harvey ras oncogene in rat esophageal papillomas induced by methylbenzylnitrosamine. Cancer Res (1990) 1.00
Growth and differentiation of human esophageal carcinoma cell lines. Cancer Res (1986) 0.97
Coamplification of the hst-1 and int-2 genes in human cancers. Jpn J Cancer Res (1988) 0.97
Amplification of the hst-1 gene in human esophageal carcinomas. Jpn J Cancer Res (1988) 0.96
Mutagens as carcinogens: development of current concepts. Mutat Res (1989) 0.95
Mutational spectrometry in animal toxicity testing. Annu Rev Pharmacol Toxicol (1990) 0.89
Cytogenetic studies of esophageal carcinoma cell lines. Cancer Genet Cytogenet (1990) 0.82
Nitrosamines and nitrosamine precursors in foods from Linxian, China, a high incidence area for esophageal cancer. Carcinogenesis (1986) 0.80
Mutation site specificity of N-nitroso-N-methyl-N-alpha-acetoxybenzylamine: a model derivative of an esophageal carcinogen. Carcinogenesis (1988) 0.80
Alkylation repair in human tissues. Basic Life Sci (1990) 0.80
p53 mutations in human cancers. Science (1991) 31.96
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (1991) 6.16
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell (1999) 5.28
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature (1982) 4.22
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res (1998) 3.74
Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A (1986) 3.42
Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A (1998) 3.35
Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci U S A (1986) 2.93
In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol (1983) 2.91
Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol (1987) 2.87
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst (1999) 2.83
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
p53 mutations in human immortalized epithelial cell lines. Carcinogenesis (1993) 2.82
GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A (1999) 2.80
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res (1996) 2.65
Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell (1985) 2.58
The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (1994) 2.49
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Heterogeneous distribution of filipin--cholesterol complexes across the cisternae of the Golgi apparatus. Proc Natl Acad Sci U S A (1981) 2.45
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res (1999) 2.36
Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res (2000) 2.31
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci (1997) 2.28
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene (1999) 2.19
Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res (1997) 2.17
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res (1998) 2.15
Improved SPECT quantification using compensation for scattered photons. J Nucl Med (1984) 2.14
Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene (1999) 2.12
Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst (1999) 2.10
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res (1991) 2.09
Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A (1993) 2.09
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00
Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol (1990) 2.00
Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J Cell Sci (1995) 1.98
Altered differentiation of mouse epidermal cells treated with retinyl acetate in vitro. Exp Cell Res (1974) 1.94
Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol (1998) 1.90
Transformation of human bronchial epithelial cells transfected by Harvey ras oncogene. Science (1985) 1.88
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Test for malignant transformation of rat liver cells in culture: cytology, growth in soft agar, and production of plasminogen activator. J Natl Cancer Inst (1977) 1.86
The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I. J Biol Chem (1999) 1.84
Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A (1993) 1.84
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (1993) 1.84
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res (2000) 1.81
Phalloidin-induced hyperplasia of actin filaments in rat hepatocytes. Lab Invest (1975) 1.78
Evaluation of the carcinogenicity of chemicals: a review of the Monograph Program of the International Agency for Research on Cancer (1971 to 1977). Cancer Res (1978) 1.73
Laminin and beta1 integrins are crucial for normal mammary gland development in the mouse. Dev Biol (1999) 1.70
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68
High-frequency transfection and cytopathology of the hepatitis B virus core antigen gene in human cells. Science (1983) 1.67
Respiratory tract carcinogenesis in hamsters induced by different numbers of administrations of benzo(a)pyrene and ferric oxide. Cancer Res (1972) 1.67
Absence of filipin-sterol complexes from large coated pits on the surface of culture cells. Proc Natl Acad Sci U S A (1979) 1.67
Tissue-mediated mutagenicity of vinylidene chloride and 2-chlorobutadiene in Salmonella typhimurium. Nature (1975) 1.66
Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res (1985) 1.66
Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res (1996) 1.65
Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine (1999) 1.65
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res (1995) 1.64
Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation (1988) 1.64
Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res (1998) 1.64
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63
Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol (1999) 1.62
Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer (1967) 1.61
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Asbestos-associated chromosomal changes in human mesothelial cells. Proc Natl Acad Sci U S A (1985) 1.60
Ultrasensitive enzymatic radioimmunoassay: application to detection of cholera toxin and rotavirus. Proc Natl Acad Sci U S A (1979) 1.58
Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res (1997) 1.58
Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer (1994) 1.57
p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet (1994) 1.56
Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol (2000) 1.56
p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med (1998) 1.55
Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci U S A (1985) 1.54
Human, rat and mouse liver-mediated mutagenicity of vinyl chloride in S. typhimurium strains. Int J Cancer (1975) 1.53
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
In vivo assembly of tight junctions in fetal rat liver. J Cell Biol (1975) 1.53
Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother (1984) 1.52
Liver-microsome-mediated formation of alkylating agents from vinyl bromide and vinyl chloride. Biochem Biophys Res Commun (1975) 1.52
Geographic variation of p53 mutational profile in nonmalignant human liver. Science (1994) 1.51
Relevance of nitrosamines to human cancer. Carcinogenesis (1984) 1.51
TGF-beta 1 influences the relative development of the exocrine and endocrine pancreas in vitro. Development (1994) 1.51
Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol (1989) 1.51